Compare Stocks: KVAC, CGEN, ADAG, and ELDN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$3.49 -2.5%	$3.81	$1.30 ▼ $4.85	$236.47M	0.56	204,551 shs	192,988 shs
CGEN Compugen	$2.56 -1.2%	$2.44	$1.29 ▼ $3.23	$244.89M	2.78	310,980 shs	192,801 shs
ELDN Eledon Pharmaceuticals	$2.93 -3.0%	$3.58	$1.35 ▼ $4.60	$245.41M	0.93	950,955 shs	1.02 million shs
KVAC Keen Vision Acquisition	$11.51	$11.92	$11.41 ▼ $18.72	$63.37M	-0.04	14,430 shs	N/A

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	-2.51%	-4.12%	-15.09%	+5.12%	+46.03%
CGEN Compugen	-1.16%	-1.16%	+6.22%	+30.61%	+76.55%
ELDN Eledon Pharmaceuticals	-2.98%	-2.66%	-20.60%	-15.32%	+13.57%
KVAC Keen Vision Acquisition	0.00%	0.00%	0.00%	-5.50%	-0.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$3.49 -2.5%	$3.81	$1.30 ▼ $4.85	$236.47M	0.56	204,551 shs	192,988 shs
CGEN Compugen	$2.56 -1.2%	$2.44	$1.29 ▼ $3.23	$244.89M	2.78	310,980 shs	192,801 shs
ELDN Eledon Pharmaceuticals	$2.93 -3.0%	$3.58	$1.35 ▼ $4.60	$245.41M	0.93	950,955 shs	1.02 million shs
KVAC Keen Vision Acquisition	$11.51	$11.92	$11.41 ▼ $18.72	$63.37M	-0.04	14,430 shs	N/A

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	-2.51%	-4.12%	-15.09%	+5.12%	+46.03%
CGEN Compugen	-1.16%	-1.16%	+6.22%	+30.61%	+76.55%
ELDN Eledon Pharmaceuticals	-2.98%	-2.66%	-20.60%	-15.32%	+13.57%
KVAC Keen Vision Acquisition	0.00%	0.00%	0.00%	-5.50%	-0.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	2.67	Moderate Buy	$10.00	186.53% Upside
CGEN Compugen	3.00	Buy	$5.00	95.31% Upside
ELDN Eledon Pharmaceuticals	2.33	Hold	$10.00	241.30% Upside
KVAC Keen Vision Acquisition	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest KVAC, CGEN, ADAG, and ELDN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	CGEN Compugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/4/2026	CGEN Compugen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/29/2026	KVAC Keen Vision Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
7/21/2026	ELDN Eledon Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/21/2026	ELDN Eledon Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/17/2026	ADAG Adagene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CGEN Compugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	ADAG Adagene	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
7/8/2026	KVAC Keen Vision Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
6/24/2026	ELDN Eledon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$9.29M	24.81	N/A	N/A	$0.75 per share	4.65
CGEN Compugen	$74.00M	3.27	$0.37 per share	6.93	$1.09 per share	2.35
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.35 per share	N/A
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$17.61M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	$35.34M	$0.38	6.74	N/A	N/A	47.56%	42.57%	26.13%	11/9/2026 (Estimated)
ELDN Eledon Pharmaceuticals	-$45.62M	-$0.91	N/A	N/A	N/A	N/A	-149.63%	-50.84%	11/13/2026 (Estimated)
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest KVAC, CGEN, ADAG, and ELDN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	KVAC Keen Vision Acquisition	N/A	$0.08	N/A	$0.08	N/A	N/A
8/13/2026	Q2 2026	ELDN Eledon Pharmaceuticals	-$0.1580	-$0.27	-$0.1120	-$0.27	N/A	N/A
8/3/2026	Q2 2026	CGEN Compugen	-$0.08	-$0.07	+$0.01	-$0.07	$1.29 million	$2.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	5.02	3.07
CGEN Compugen	N/A	5.72	5.72
ELDN Eledon Pharmaceuticals	N/A	7.90	7.90
KVAC Keen Vision Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
CGEN Compugen	12.22%
ELDN Eledon Pharmaceuticals	56.77%
KVAC Keen Vision Acquisition	51.72%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
CGEN Compugen	9.50%
ELDN Eledon Pharmaceuticals	9.60%
KVAC Keen Vision Acquisition	80.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	66.05 million	52.05 million	Not Optionable
CGEN Compugen	70	94.55 million	85.57 million	Optionable
ELDN Eledon Pharmaceuticals	10	81.26 million	73.46 million	Optionable
KVAC Keen Vision Acquisition	N/A	5.51 million	1.09 million	Not Optionable

KVAC, CGEN, ADAG, and ELDN Headlines

Recent News About These Companies

Short Interest in Keen Vision Acquisition Corporation (NASDAQ:KVAC) Grows By 1,480.3%

August 11, 2026 | marketbeat.com

Keen Vision Extends Timeline for Business Combination Deal

July 28, 2026 | tipranks.com

Keen Vision Acquisition Extends SPAC Deadline with Sponsor Note

April 27, 2026 | tipranks.com

Keen Vision, Medera Extend Timeline for Revised Merger

April 15, 2026 | tipranks.com

Keen Vision Signs New Letter of Intent with Novoheart

March 2, 2026 | tipranks.com

Keen Vision Extends SPAC Timeline and Secures Funding

January 26, 2026 | tipranks.com

Keen Vision Acquisition Extends Business Combination Deadline

January 5, 2026 | tipranks.com

Keen Vision Issues Promissory Note for Business Extension

November 24, 2025 | tipranks.com

Keen Vision Acquisition (NASDAQ:KVAC) Trading 0.5% Higher â€“ Still a Buy?

November 22, 2025 | defenseworld.netD

Keen Vision Extends Business Combination Deadline

September 25, 2025 | tipranks.com

Keen Vision Transfers Funds to Trust Account

September 2, 2025 | tipranks.com

Keen Vision Issues Promissory Note to Extend Merger Time

August 22, 2025 | tipranks.com

KVAC Keen Vision Acquisition Corporation - Seeking Alpha

June 29, 2025 | seekingalpha.com

Keen Vision Issues Promissory Note to Extend Deadline

June 27, 2025 | tipranks.com

Keen Vision Acquisition Corporation (KVACW) - Yahoo Finance

June 27, 2025 | au.finance.yahoo.com

Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025

June 13, 2025 | globenewswire.com

Keen Vision Acquisition Corporation Ordinary Shares

June 6, 2025 | fxempire.comF

Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress

May 12, 2025 | globenewswire.com

Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

April 1, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/04/01/3053271/0/en/medera-presented-updated-results-from-first-in-human-gene-therapy-trial-for-heart-failure-with-preserved-ejection-fraction-at-2025-hfpef-summit.html$

Keen Vision Acquisition Corp. Secures Funding to Extend Merger Deadline

March 30, 2025 | investing.com

Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

March 20, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/03/20/3046150/0/en/medera-receives-dsmb-clearance-to-initiate-phase-2-portion-of-music-hfref-phase-1b-2-trial-for-srd-001-gene-therapy-in-heart-failure-with-reduced-ejection-fraction.html$

New MarketBeat Followers Over Time

Media Sentiment Over Time

KVAC, CGEN, ADAG, and ELDN Company Descriptions

Adagene NASDAQ:ADAG

$3.49 -0.09 (-2.51%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$3.48 -0.01 (-0.17%)

As of 04:09 AM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Compugen NASDAQ:CGEN

$2.56 -0.03 (-1.16%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$2.56 +0.00 (+0.20%)

As of 05:28 AM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Eledon Pharmaceuticals NASDAQ:ELDN

$2.93 -0.09 (-2.98%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$2.91 -0.02 (-0.82%)

As of 04:43 AM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Keen Vision Acquisition NASDAQ:KVAC

$11.51 0.00 (0.00%)

As of 09/4/2026

Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KVAC, CGEN, ADAG, and ELDN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KVAC, CGEN, ADAG, and ELDN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KVAC, CGEN, ADAG, and ELDN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KVAC, CGEN, ADAG, and ELDN Company Descriptions

Adagene NASDAQ:ADAG

Compugen NASDAQ:CGEN

Eledon Pharmaceuticals NASDAQ:ELDN

Keen Vision Acquisition NASDAQ:KVAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KVAC, CGEN, ADAG, and ELDN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KVAC, CGEN, ADAG, and ELDN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KVAC, CGEN, ADAG, and ELDN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KVAC, CGEN, ADAG, and ELDN Company Descriptions

Adagene NASDAQ:ADAG

Compugen NASDAQ:CGEN

Eledon Pharmaceuticals NASDAQ:ELDN

Keen Vision Acquisition NASDAQ:KVAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools